Cargando…
Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
BACKGROUND: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195750/ https://www.ncbi.nlm.nih.gov/pubmed/30342531 http://dx.doi.org/10.1186/s12944-018-0888-0 |
_version_ | 1783364449348878336 |
---|---|
author | Martinelli, Ana Elisa M. Maranhão, Raul C. Carvalho, Priscila O. Freitas, Fatima R. Silva, Bruna M. O. Curiati, Milena N. C. Kalil Filho, Roberto Pereira-Barretto, Antonio Carlos |
author_facet | Martinelli, Ana Elisa M. Maranhão, Raul C. Carvalho, Priscila O. Freitas, Fatima R. Silva, Bruna M. O. Curiati, Milena N. C. Kalil Filho, Roberto Pereira-Barretto, Antonio Carlos |
author_sort | Martinelli, Ana Elisa M. |
collection | PubMed |
description | BACKGROUND: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such as lipid transfer, cholesterol ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) concentration. METHODS: Twenty-five HF patients in NYHA class I/II and 23 in class III/IV were enrolled. Plasma lipids, apolipoproteins, CETP, LCAT, oxidized-LDL (oxLDL) and paraoxonase-1 (PON-1) activity were determined. Lipid transfer from a donor artificial nanoparticle to HDL was measured by in vitro assay. RESULTS: Total cholesterol (p = 0.049), LDL-C (p = 0.023), non-HDL-C (p = 0.029) and CETP, that promotes lipid transfer among lipoproteins (p = 0.013), were lower in III/IV than in I/II group. Triglycerides, HDL-C, apo A-I, apo B, oxLDL, LCAT, enzyme that catalyzes serum cholesterol esterification, PON-1 activity, and in vitro transfers of cholesterol, triglycerides and phospholipids to HDL, important steps in HDL metabolism, were equal. IL-8 was higher in III/IV (p = 0.025), but TNFα, IL-1β, IL-6 and MCP-1 were equal. BNP was negatively correlated with CETP (r = − 0.294; p = 0.042) and positively correlated with IL-8 (r = 0.299; p = 0.039). CONCLUSIONS: Our results disclosed the relationship between CETP levels and HF severity, by comparing two HF groups and by correlation analysis. Lower CETP levels may be a marker of HF aggravation and possibly of worse prognosis. Practical applications of this initial finding, as the issue whether CETP could be protective against HF aggravation, should be explored in larger experimental and clinical studies. |
format | Online Article Text |
id | pubmed-6195750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61957502018-10-30 Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure Martinelli, Ana Elisa M. Maranhão, Raul C. Carvalho, Priscila O. Freitas, Fatima R. Silva, Bruna M. O. Curiati, Milena N. C. Kalil Filho, Roberto Pereira-Barretto, Antonio Carlos Lipids Health Dis Research BACKGROUND: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such as lipid transfer, cholesterol ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) concentration. METHODS: Twenty-five HF patients in NYHA class I/II and 23 in class III/IV were enrolled. Plasma lipids, apolipoproteins, CETP, LCAT, oxidized-LDL (oxLDL) and paraoxonase-1 (PON-1) activity were determined. Lipid transfer from a donor artificial nanoparticle to HDL was measured by in vitro assay. RESULTS: Total cholesterol (p = 0.049), LDL-C (p = 0.023), non-HDL-C (p = 0.029) and CETP, that promotes lipid transfer among lipoproteins (p = 0.013), were lower in III/IV than in I/II group. Triglycerides, HDL-C, apo A-I, apo B, oxLDL, LCAT, enzyme that catalyzes serum cholesterol esterification, PON-1 activity, and in vitro transfers of cholesterol, triglycerides and phospholipids to HDL, important steps in HDL metabolism, were equal. IL-8 was higher in III/IV (p = 0.025), but TNFα, IL-1β, IL-6 and MCP-1 were equal. BNP was negatively correlated with CETP (r = − 0.294; p = 0.042) and positively correlated with IL-8 (r = 0.299; p = 0.039). CONCLUSIONS: Our results disclosed the relationship between CETP levels and HF severity, by comparing two HF groups and by correlation analysis. Lower CETP levels may be a marker of HF aggravation and possibly of worse prognosis. Practical applications of this initial finding, as the issue whether CETP could be protective against HF aggravation, should be explored in larger experimental and clinical studies. BioMed Central 2018-10-20 /pmc/articles/PMC6195750/ /pubmed/30342531 http://dx.doi.org/10.1186/s12944-018-0888-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Martinelli, Ana Elisa M. Maranhão, Raul C. Carvalho, Priscila O. Freitas, Fatima R. Silva, Bruna M. O. Curiati, Milena N. C. Kalil Filho, Roberto Pereira-Barretto, Antonio Carlos Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
title | Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
title_full | Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
title_fullStr | Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
title_full_unstemmed | Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
title_short | Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
title_sort | cholesteryl ester transfer protein (cetp), hdl capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195750/ https://www.ncbi.nlm.nih.gov/pubmed/30342531 http://dx.doi.org/10.1186/s12944-018-0888-0 |
work_keys_str_mv | AT martinellianaelisam cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT maranhaoraulc cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT carvalhopriscilao cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT freitasfatimar cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT silvabrunamo cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT curiatimilenanc cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT kalilfilhoroberto cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure AT pereirabarrettoantoniocarlos cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure |